The main objective of this study was to investigate thermosensitive Pluronic® F-127 (PF-127) hydrogel for the modified release of a potent alcohol and opioid antagonist, naltrexone (NTX) hydrochloride, in a subcutaneous injectable dosage form.
The NTX hydrogels were prepared by the cold method, and the in vitro release profiles of various formulations were evaluated at 37°C using the Franz diffusion cell system. We examined the different PF-127 concentrations, pH of solution, and inorganic salts on drug release from these gels.
The data showed an increase in PF-127 content from 20% to 35%, resulting in a decrease in the rate of NTX release. Among the formulations prepared in different pH solutions, pH 7.4 produced the slowest drug release rate. The addition of inorganic salts had no significant effect on drug release. However, these factors appeared to have limited effects on drug release rate. Therefore, to achieve a sustained-release formulation, a NTX and triacetyl β-cyclodextrin (TAβCD) complex was evaluated. The binary systems of NTX/TAβCD in different molar ratios were prepared by the kneading method, and complex formation was demonstrated by differential scanning calorimetry.
The results of the current in vitro study indicate that PF-127 gel formulations containing drug complexes with hydrophobic cyclodextrin could be useful for the preparation of a controlled delivery system of water-soluble drugs such as NTX, for a period of more than 140 hours.
The usefulness of naltrexone in opioid dependence is limited by low retention during treatment. Naltrexone (NTX) temporarily blocks substance intake and does not affect craving. Sustained-release preparations of NTX have shown rather promising results. The development of new injectable drug delivery systems has received considerable attention over the past few years.
PF-127, or poloxamer 407 (Pluronic®) is a commercially available polyoxyethylene-propylene copolymer, of general formula E106 P70 E106, with an average molar mass of 13,000.
This kind of depot-like sustained release gel is available for many drugs, but there have been no published reports of its use for delivery of NTX. Oral NTX is safe and effective for the treatment of both alcohol and opioid dependence. However, because of its extensive first-pass metabolism, small treatment effect, plasma level fluctuations, adverse events, and poor patient adherence to the daily dosing schedule, clinical acceptance of this dosage form has been limited.
Due to the high solubility of NTX (65 mg/mL) and the amphiphilic nature of PF-127, it appears that drug release from the carrier may be rapid and characterized by a strong burst of drug release.
Hydrophobic cyclodextrins, such as triacetyl-β-cyclodextrin (TaβCD,
The most common preparation method for complexes with hydrophobic cyclodextrins is the kneading technique.
To confirm the formation of a NTX/TAβCD complex, each sample was analyzed by differential scanning calorimetry.
NTX, PF-127, and TAβCD were purchased from Sigma-Aldrich (Schrelldorf, Germany). Analytical grade ethanol and inorganic salts were obtained from Merck (Darmstadt, Germany). Cellulose acetate membrane (molecular weight cutoff 12,000 Da) was obtained from Sigma (Germany). All other chemical reagents used were of pharmaceutical grade.
The PF-127 solutions were prepared by the cold method.
An appropriate amount of NTX (10 mg/mL) was added to each formulation. All gels were kept overnight at 4°C until a homogenous solution was obtained.
The binary system of NTX/TAβCD in different molar ratios (1:1, 1:2, and 1:4) was prepared by the kneading method, ie, TAβCD was wetted in a ceramic mortar with ethanol:water 50% (v/v) solution until a paste was obtained. The required amount of NTX was then added slowly whilst grinding, and the slurry was kneaded for about 45 minutes. During this process, an appropriate quantity of solvent was added in order to maintain a suitable consistency. The product was then dried at 40°C over 24 hours and added to the poloxamer solution.
The optimum NTX/TAβCD complex was characterized by thermal analysis, performed using a differential scanning calorimeter (DSC-60, Shimadzu Co., Kyoto, Japan). Thermograms of the different samples (inclusion complex, physical mixture, and pure substances) were obtained from differential scanning calorimetry equipped with a thermal analysis data system. Weighted samples (6–8 mg) were contained in sealed aluminum pans and scanned at a rate of 10°C/min, between 0°C and 300°C, using nitrogen as a purging gas. The thermal analysis was carried out over 300°C during preliminary runs, but only thermal events observed over 240°C involved decomposition of the materials.
In this study, diffusion cells were used to evaluate NTX release from the poloxamer hydrogels.
Phosphate-buffered solutions (pH 7.4) containing different concentrations of PF-127 (20%, 25%, 30%, and 35% [w/v]) without any additive were prepared as described above. The in vitro release of NTX from these gel formulations was studied.
The effect of pH on drug release was studied using 25% (w/v) PF-127 gels. These formulations were prepared in different pH solutions, ie, 5.5, 7.4, and 8.5, using 0.2 M phosphate buffer.
The effect of salts was studied using 25% Pluronic formulations of NTX in the presence of NaCl, Na2SO4, and Na2HPO4 (1% w/v). The PF-127 gel formulation with no additive was used as a control.
The effect of TAβCD was studied using a gel containing PF-127 25% (w/v) and binary systems of NTX/TAβCD in different molar ratios which were prepared by the kneading method. The PF-127 gel formulation with no additive was used as a control.
The effect of PF-127 concentration (20%, 25%, 30%, and 35%) on drug release at 37°C is shown in
A hydration layer surrounds PF-127 molecules at low temperatures in aqueous solution. However, when the temperature is raised, the hydrophilic chains of the copolymer become desolvated as a result of the breakage of the hydrogen bonds that had been established between the solvent and these chains. This phenomenon favors hydrophobic interactions among the poly oxypropylene domains, leading to increased chain entanglement and gel formation.
The effect of pH on NTX release was studied at vehicle pH values of 5.5, 7.4, and 8.5 using 25% PF-127 phosphate-buffered solutions (
Most pharmaceutical PF-127 gels are formulated with salts, either for buffering or ionic strength adjustment.
The release profiles of NTX and NTX/TAβCD binary systems in different molar ratios incorporated into 25% w/v PF-127 formulations are presented in
Problems in controlling drug release from polymeric carriers are common, particularly for matrices composed of hydrophilic polymers, eg, PF-127 hydrogels. In such cases, drug release from the carrier may be rapid and characterized by a burst release.
Poorly water-soluble alkylated cyclodextrin derivatives, such as TaβCD, are useful as slow-release carriers for water soluble drugs.
TAβCD forms noncovalent and poorly water soluble complexes with NTX and reduced drug solubility in aqueous medium and total concentration of diffusible species, resulting in a retarded release. In vitro release experiments showed that the formulations containing drug/TAβCD in molar ratios of 1:2 and 1:4 with no significant difference were able to prolong and control NTX release for more than 144 hours. The optimum formulation showed more than three-week stability at refrigerator temperature and 72 hours at 37°C.
The solid binary systems were analyzed by means of differential scanning calorimetry to detect possible altered thermal properties with regard to the pure substances. When guest molecules are incorporated in the TAβCD cavity, their melting, boiling, and sublimation points generally shift to a different temperature or disappear at the temperature range within which the cyclodextrin lattice is decomposed.
For a novel drug delivery system, one of the major advantages is extending product life through formulation, and decreasing the number of times that a product is administered. Several approaches have been used to improve the prolonged release dosage forms to increase patient compliance. One of these approaches is the utilization of Pluronic F-127 hydrogels. In this study, we developed a new sustained release and thermoresponsive drug delivery system for a potent opioid receptor antagonist, NTX, to be administrated subcutaneously. Poloxamer hydrogel formulations containing NTX were evaluated by in vitro experiments. The results showed that the release of NTX from PF-127 hydrogel was affected by formulation variables of the gel. Increasing F127 concentration in the gel decreases drug release rate. The pH of the polymeric solution is also an important factor for NTX release. The addition of inorganic salts has no significant effect on drug release. The present results suggested that a combination of TAβCD/drug complexes and Pluronic gels with sustained-release behavior for more than 144 hours is useful for the controlled release of a water-soluble drug, and the release rate may be controlled by adjusting the molar ratio of the components.
This work was supported by a grant from the Faculty of Pharmacy, Kermanshah University of Medical Sciences, Iran.
The authors report no conflicts of interest in this work.
Chemical structure of naltrexone and triacetyl-β-cyclodextrin (TAβCD).
Influence of PF-127 concentration on naltrexone release from hydrogel formulations.
In vitro release profiles of naltrexone from 25% PF-127 hydrogel formulations prepared in different pH solutions. Each point represents the mean ± standard deviation (n = 3).
Effect of inorganic salts addition on release of naltrexone from 25% PF-127 hydrogel. Each point represents the mean ± standard deviation (n = 3).
Release profiles of naltrexone from 25% PF-127 gel formulations containing binary naltrexone/triacetyl-β-cyclodextrin systems in different molar ratios. Each point represents the mean ± standard deviation (n = 3).
Differential scanning calorimetry thermograms of